The headline result: in the 2024 PROFILE trial, 79% of newly-diagnosed Crohn's patients on top-down therapy were in lasting remission a year later without steroids or surgery, compared with 15% on the old step-up approach. Fewer side effects. Fewer operations. Five-year follow-up shows no extra infections or cancers either. The catch is honest: these drugs are expensive, require ongoing infusions or injections, and a minority of people stop responding to them over time. But the case for waiting has collapsed.
Crohn's disease and ulcerative colitis are driven by the immune system attacking the lining of the gut. A small protein called tumour necrosis factor — TNF-α — is one of the loudest signals telling immune cells to keep attacking. The first generation of biologics (infliximab, adalimumab) are antibodies designed to grab onto TNF-α and shut it up. Newer biologics block different signals — interleukin-23 (risankizumab, ustekinumab) or the trafficking molecule that lets immune cells home to the gut (vedolizumab). All of them turn down the inflammation that an ordinary anti-inflammatory like a steroid can only briefly suppress.
The reason early matters is mechanical, not philosophical. Crohn's disease moves through a relatively brief inflammatory window — months to a few years — and then begins to scar. The bowel wall thickens and narrows. Tunnels (fistulas) burrow out to the skin or to other organs. Once that scarring is laid down, no drug can dissolve it; the only treatment is surgery to cut out the damaged segment. The window when biologics can actually change the disease's path is the same window when people are most likely to be put on steroids and watched.
What the trials actually show
Four big randomised trials have asked some version of the same question — "start strong vs build up slowly" — and all four landed in the same place. The first was small and pointed the way. The most recent was large enough to settle the matter.
The earlier trials had already shown the direction. The original 2008 study — the one that coined the term "top-down" — found 60% steroid-free remission at one year on combined infliximab plus azathioprine, versus 36% on the classic step-up sequence D'Haens et al. 2008. SONIC, a 508-patient trial in 2010, showed that infliximab plus azathioprine together produced steroid-free remission in 57% of newly-diagnosed Crohn's patients, versus 44% for infliximab alone and 30% for azathioprine alone — and that the combination produced cleaner mucosal healing on follow-up colonoscopy than any single drug Colombel et al. 2010. A pragmatic community-practice trial called REACT showed that gastroenterology clinics randomised to escalate fast to combined biologic therapy had lower rates of surgery, hospitalisation and serious complications at two years than clinics using conventional care Khanna et al. 2015. CALM showed that letting symptoms alone decide when to escalate consistently under-treats inflammation; using a blood marker (CRP) and a stool marker (faecal calprotectin) to trigger escalation produces more mucosal healing at one year Colombel et al. 2017.
All four trials enrolled moderate-to-severe disease — that is the population this evidence speaks to. The European and American gastroenterology societies updated their guidelines in 2024 and 2025 in response: the AGA now explicitly suggests starting with an advanced therapy over starting with steroids in moderate-to-severe Crohn's disease AGA 2025, and ECCO has aligned ECCO 2024.
What waiting actually costs
The step-up sequence sounds cautious. It is not. It is a series of years in which you are likely on a steroid — and the steroid is doing its own damage while you wait to qualify for the drug that would have worked.
The Olmsted County natural-history cohort is the cleanest picture of what step-up actually delivers. Of newly-diagnosed Crohn's patients put on a steroid course, 28% became steroid-dependent within one year — meaning they couldn't taper off without flaring. 16% became outright steroid-resistant. 38% needed Crohn's-related surgery within that same year Faubion et al. 2001. Steroid exposure itself, on multivariable analysis of patients followed for the development of bowel strictures, more than doubles the risk of progression to stricturing disease. The drug that was supposed to be a bridge becomes the road.
The felt experience of those years is its own kind of damage. People around you start asking why your face looks puffy. You're awake at 3 a.m. because the prednisone won't let you sleep. Your skin breaks out the way it didn't even in your teens. You gain twenty pounds you didn't intend. Your mood swings in ways your partner notices before you do. None of this counts as a complication on a chart — but it is what waiting for the strong drug actually feels like.
And underneath the steroid years, the disease keeps remodelling the bowel. The five-year version of the patient who didn't go top-down has typically tried two or three drug classes in sequence, been hospitalised at least once, had bowel-wall thickening visible on imaging, and is being told it might be time to discuss surgery. The five-year top-down patient, in most cases, is at work, on the same drug they started with, with a normal colonoscopy.
How top-down actually runs
The strategy is a strategy, not a single prescription. Your gastroenterologist picks the biologic — usually infliximab or adalimumab to start in Crohn's, vedolizumab often preferred first-line in ulcerative colitis — and almost always pairs it with an immunomodulator like azathioprine or methotrexate for the first year or two. The pairing matters: it cuts the rate at which your body learns to neutralise the biologic from about 13% down to about 4% Colombel et al. 2010.
Most people feel a real shift within two to six weeks of the first infusion or injection. Night-time symptoms — the urgent run to the bathroom at 3 a.m. — tend to resolve first. Daytime bowel-movement frequency drops next. Pain follows. Fatigue is slowest to lift and tracks the inflammation calming over two to four months.
When this isn't the move
Pregnancy is not a reason to delay or stop. The current ECCO and AGA guidance is explicit: anti-TNF drugs are continued through pregnancy because uncontrolled inflammatory bowel disease is the bigger risk to the baby ECCO 2024. Mild disease — not the moderate-to-severe disease this article addresses — is the other "not the move" case; the trial evidence does not extend to people whose disease would settle on its own with milder treatment.
What most guides still get wrong
"Step-up is the safer choice — the biologic carries too much long-term risk to start early." This was the cautious-sounding default for two decades. It's the framing the new data unwound. The right comparison isn't "biologic versus nothing." It's "biologic versus cumulative steroids plus ongoing inflammation." On that comparison, every published meta-analysis and the five-year PROFILE follow-up show no excess in serious infections or cancers in the top-down arm versus the step-up arm Noor et al. 2024, Singh et al. 2020.
"A blood test will tell us if you really need the strong drug." This was the hope. PROFILE specifically tested the best-validated T-cell blood biomarker — a tool called PredictSURE-IBD — to see whether it could pick out the high-risk patients who needed top-down from the low-risk patients who'd do fine with step-up. It found the biomarker added nothing: every subgroup did better with top-down. As of 2026, no blood test reliably identifies the moderate-to-severe patient who can safely wait.
"Once you start a biologic, you're on it forever." Mostly true, but not entirely. After two to three years of stable remission with combination therapy, some people taper the immunomodulator and stay on the biologic alone. A smaller group eventually trial full withdrawal under close monitoring. The current default is to plan for the long haul and revisit later, not to lock the decision in stone.
Where this goes wrong in practice
About one in four to one in three people who start an anti-TNF drug don't get a real response to it. The two failure modes are different and need different responses.
Primary non-response. The drug doesn't work in the first place. Roughly 10–40% across published trials, perhaps 10–20% in real-world clinics Kennedy et al. 2019. The signal is no meaningful improvement in symptoms, blood markers, or stool calprotectin by week 12 to 14. The move is to check drug levels — sometimes the issue is that the dose was too low for that person's body — and if levels look fine, switch to a different class of biologic (anti-IL-23 like risankizumab or ustekinumab, or anti-integrin like vedolizumab).
Secondary loss of response. The drug worked, then stopped working. Around 13–26% per year in maintenance. The usual cause is that the immune system has started making antibodies against the biologic — recognising the drug as foreign — and clearing it from the bloodstream faster than it can take effect. This is exactly why an immunomodulator is paired alongside in the top-down protocol: combination therapy roughly cuts the rate of these neutralising antibodies in half Colombel et al. 2010. When loss of response happens, the moves are dose escalation, drug-level testing, or class-switching.
Cost, access, and what daily life looks like
Money is the constraint that most often gets in the way. Originator infliximab and adalimumab were historically priced at twenty-five to fifty thousand dollars a year in the United States. The arrival of biosimilars — chemically equivalent copies, the way generic ibuprofen relates to brand-name Advil — has compressed those prices by 50–60% since 2017, and is still moving. In single-payer health systems like the UK NHS, biosimilars dominate the market and the drug is genuinely affordable; the PROFILE cost-effectiveness analysis found top-down infliximab actually saves the NHS about £1,681 per patient over five years, and adalimumab biosimilars save about £10,000 Lee et al. 2025.
In the US, even with good insurance, expect coinsurance and copays to push out-of-pocket cost into the thousands a year. Manufacturer patient-assistance programmes (Janssen's CarePath for Remicade, AbbVie's program for Humira, etc.) can drop infusion costs to about $5 per infusion for commercially-insured patients, capped at $20,000 per calendar year. Ask the infusion centre and the drug-maker's patient-support line on day one; never assume the listed price is what you'll pay.
Time-wise: an infliximab infusion is about half a day at an infusion centre every two months — two hours of dripping, an hour of observation, drive time on either end. Subcutaneous infliximab and adalimumab convert that to a self-injection every two weeks at home. Most people get used to the injection in a few sessions; the needle is short and the dose is small. Blood draws every three to six months. A follow-up colonoscopy once a year for the first few years.
What else could go in the top-down slot
"Top-down" names a strategy, not a particular drug. The trial evidence is strongest for anti-TNF drugs (infliximab and adalimumab) because they've been studied the longest, but the strategy now has several modern options:
- Anti-IL-23 drugs (risankizumab, mirikizumab, guselkumab) and anti-IL-12/23 (ustekinumab). Block a different inflammatory signal. Roughly match anti-
TNFon effectiveness in moderate-to-severe Crohn's, with a cleaner safety profile and less immunogenicity. The AGA 2025 guideline lists them alongside infliximab and adalimumab as high-efficacy first choices AGA 2025. - Vedolizumab. Blocks immune cells from trafficking into the gut, rather than damping inflammation throughout the body. The "gut-only" mechanism makes it the preferred choice for older patients, anyone with a recent cancer history, or anyone who can't take a systemic immune-suppressant. It's often the first-line choice for moderate-to-severe ulcerative colitis.
- JAK inhibitors (upadacitinib, tofacitinib). Oral pills rather than injections. Fast onset. Carry a black-box warning for cardiovascular events and certain cancers in older patients with cardiovascular risk factors; the trade-off is real.
The partial-credit alternative is accelerated step-up with tight monitoring — using stool calprotectin and blood CRP rather than symptoms alone to gate the escalation to biologic. This was the PROFILE comparator arm and still lost decisively to leading with the biologic Noor et al. 2024. It's better than symptom-only step-up but it isn't the same thing as top-down.
What changes when this works
The honest forecast, rung by rung:
The first six weeks. The 3 a.m. bathroom run stops. You sleep through. The bowel-movement count falls from eight or ten a day to two or three. Blood in the stool fades. The constant low-grade abdominal ache eases. The PROFILE patients on top-down hit their first major clinical response at a median of around the six-week mark Noor et al. 2024.
The first three months. Energy comes back, slowly. The exhaustion that came with active inflammation lifts the way a fever lifts — you don't notice it disappearing, you notice one morning that you didn't dread getting up. Weight starts to settle. You stop having to map every trip around where the bathrooms are. The colleague who'd stopped asking how you were doing starts again, in a different tone.
The first year. The follow-up colonoscopy at six to twelve months — the test that actually matters, because it shows whether the gut lining itself has healed — comes back with normal-looking tissue in the majority of top-down patients. That mucosal-healing finding is what predicts the long arc: people who reach it have markedly lower rates of flares, hospitalisations and surgery over the years that follow.
The five-year horizon. The PROFILE patients followed out to five years showed durable benefit — sustained remission, no excess infections, no excess cancers compared with step-up. Most are still on the same drug they started with. A few have been able to taper or switch. The step-up parallel-universe version of the same patient has typically tried two or three drug classes, been hospitalised, possibly had bowel resection, and is older both literally and biologically.
The decade. This is the part the trials can't tell you yet. The long-arc question — does early biologic therapy bend the natural history of inflammatory bowel disease on a decades scale? — is still under study. The directional evidence (declining colectomy rates in the biologic era, lower complication rates in cohorts started early) all points the same way. The honest answer is that the case is strong and the formal confirmation is still being built.
What else is worth looking into
A few adjacent topics if you've gone down this road:
- Faecal calprotectin testing — the stool inflammation marker that lets you know if your gut is quiet between colonoscopies. Cheaper, less invasive, and the modern monitoring standard.
- Therapeutic drug monitoring for biologics — measuring drug levels and anti-drug antibodies to spot loss of response before it becomes a flare.
- Nutritional therapy in Crohn's disease — exclusive enteral nutrition has its own evidence base, especially in paediatric and newly-diagnosed Crohn's.
- Smoking and Crohn's disease — one of the largest modifiable factors in long-term outcomes; cessation matters more than almost any drug choice.
- Iron deficiency anaemia in IBD — the most common cause of the brain-fog and exhaustion that persists even after disease control.
- Mental-health support alongside IBD — disease and depression travel together; treating both produces better outcomes than treating either alone.
- — Biologics dial down your immune system, so it's best to get vaccines sorted before you start — live ones especially.
- — For ulcerative colitis, curcumin as an add-on cut relapse fourfold — handy alongside, not instead of, the biologic doing the heavy lifting.
- — Catching IBD early through its red flags is what makes the top-down biologic strategy possible.
- — The same TNF biologics treat both conditions, and HS shows up more often in people with Crohn's — they share inflammatory wiring.
- — Same class of drug, different disease — biologics that shut inflammation down at the source.
Substance and claimed effects
"Top-down" therapy for inflammatory bowel disease (IBD) is the strategy of initiating a biologic agent — typically an anti-tumor-necrosis-factor (anti-TNF) monoclonal antibody such as infliximab or adalimumab, often combined with an immunomodulator (azathioprine or methotrexate) — at or shortly after diagnosis in patients with moderate-to-severe Crohn's disease (CD) or ulcerative colitis (UC). It is the explicit alternative to the historical "step-up" approach, which begins with 5-aminosalicylates and/or systemic corticosteroids, escalates to immunomodulator monotherapy if disease persists, and reserves biologics for refractory or complicated cases. Newer agents now used in the top-down position include the IL-23 inhibitors risankizumab, mirikizumab and guselkumab; the IL-12/23 inhibitor ustekinumab; the gut-selective integrin inhibitor vedolizumab; and the oral JAK inhibitors upadacitinib and tofacitinib. The claimed consequences cluster around four endpoints: higher rates of sustained steroid-free clinical remission; higher rates of endoscopic mucosal healing; lower cumulative steroid exposure and its iatrogenic harms; and reduction of long-term complications — bowel-wall damage, strictures, fistulas, hospitalizations and surgery. Secondary felt-experience consequences follow from disease control: resolution of fatigue, normalization of bowel function, reduction of pain, return of weight and appetite, and partial reversal of the depression and anxiety that co-vary with active inflammation.
Evidence by addressing question
Mechanism
The biological argument has two layers. The first is the pharmacology of the agents themselves: infliximab is a chimeric IgG1 monoclonal antibody that binds both soluble and membrane-bound TNF-α, neutralizing its signalling, inducing apoptosis of inflammatory T cells and monocytes, downregulating downstream cytokine cascades (IFN-γ, IL-6), inducing FOXP3+ regulatory T cells, normalizing endothelial function and restoring matrix metalloproteinase / TIMP balance to permit mucosal repair Hanauer et al. 2002. The second is the "window of opportunity" hypothesis. Cross-sectional natural-history data show that approximately 20% of patients with Crohn's disease develop penetrating or stricturing complications within 90 days of diagnosis, rising to ~50% by 20 years post-diagnosis. The hypothesis is that the disease passes through a predominantly inflammatory phase early on, before fibrostenotic remodelling, fistulization and surgery have produced irreversible bowel damage; anti-inflammatory pharmacology is therefore mechanistically positioned to alter disease trajectory only if delivered before that remodelling is established. Once a stricture has fibrosed or a fistula has tracked, no biologic reverses the damage; the same drug delivered three years later acts on a different tissue substrate.
Evidence
The randomised-trial evidence base is large and unusually consistent across two decades.
D'Haens 2008 (Lancet). The original "top-down vs step-up" trial randomised 133 newly diagnosed, immunomodulator- and biologic-naïve CD patients to either early combined infliximab + azathioprine or conventional step-up (corticosteroid induction, with azathioprine added only on flare). At week 52, 60% of the top-down group were in steroid-free remission without surgery or resection vs 36% of the step-up arm; at 2 years the advantage persisted, with significantly higher mucosal healing on endoscopy in the top-down group D'Haens et al. 2008. The trial was open-label and modest in size, but it established the conceptual frame.
SONIC 2010 (NEJM). 508 immunomodulator- and biologic-naïve adults with moderate-to-severe CD were randomised to infliximab monotherapy, azathioprine monotherapy, or infliximab + azathioprine. At week 26, steroid-free remission was achieved by 56.8% on combination, 44.4% on infliximab, and 30.0% on azathioprine; mucosal healing rates followed the same hierarchy. Combination therapy also halved the rate of anti-drug antibody formation against infliximab (≈4% vs ≈13%), explaining part of its durability advantage Colombel et al. 2010.
REACT 2015 (Lancet). A pragmatic cluster-randomised trial across 41 community gastroenterology practices in Belgium and Canada. Practices were randomised to an early combined immunosuppression (ECI) algorithm — accelerated to anti-TNF + immunomodulator on any failure of steroid induction — or to conventional care. At 2 years, the ECI arm showed a significantly lower composite rate of surgery, hospitalization, and serious disease-related complications, although the primary endpoint of clinical remission at one year did not differ between arms Khanna et al. 2015.
CALM 2017 (Lancet). 244 patients with active early CD were randomised to symptom-driven escalation (clinical management) versus "tight control" — escalation also triggered by elevated C-reactive protein or faecal calprotectin. Both arms used the same drug ladder (corticosteroid → adalimumab → adalimumab weekly + azathioprine). At week 48, the proportion in mucosal healing was 46% with tight control vs 30% with symptom-driven management Colombel et al. 2017. CALM is a treat-to-target trial rather than a pure top-down trial, but it established that letting symptoms alone gate biologic escalation systematically under-treats inflammation.
PROFILE 2024 (Lancet Gastroenterol Hepatol). The most recent, largest, and methodologically tightest test of the strategy. 386 newly-diagnosed CD adults across 40 UK hospitals were randomised at a median of 12 days post-diagnosis to either top-down infliximab + immunomodulator from week 0 or an accelerated step-up algorithm (steroid taper → immunomodulator at flare → infliximab at second flare). The primary endpoint, sustained steroid-free and surgery-free remission at week 48, was achieved by 79% (149/189) of the top-down group vs 15% (29/190) of the step-up group — a 64-percentage-point absolute difference (95% CI 57 to 72; p<0.0001). Adverse events were lower in the top-down arm (168 vs 315), as were serious adverse events (15 vs 42) and abdominal surgeries (1 vs 10); serious infections did not differ (3 vs 8) Noor et al. 2024. PROFILE also tested a blood T-cell transcriptional biomarker (PredictSURE-IBD) for treatment stratification — there was no biomarker–treatment interaction, meaning every subgroup benefitted from top-down. Five-year follow-up data, presented at ECCO 2026, showed no excess in serious infections (7% vs 8%) or malignancies (3% vs 2%) in the top-down arm and persistent inferiority of the step-up arm even when anti-TNF was started within six months.
Ulcerative colitis. Direct head-to-head top-down vs step-up RCTs are scarcer in UC than in CD. Infliximab efficacy in moderate-to-severe UC was established by ACT 1 and ACT 2 Rutgeerts et al. 2005. Observational cohorts and a 2024 evidence review concluded that early biologic initiation (within 36 months of diagnosis) improved clinical remission, mucosal healing and colectomy rates; population-based time-trend analyses show a 30–60% reduction in colectomy rates over the biologic era in most jurisdictions, although Israeli data dissent. Vedolizumab vs infliximab head-to-head data in UC favour vedolizumab on safety and possibly endoscopic response (78% vs 63% in a 297-patient cohort presented at AIBD 2024), without RCT confirmation.
Practice / clinical consensus
The 2024 ECCO Guidelines on Therapeutics in Crohn's Disease recommend adalimumab, infliximab, ustekinumab, certolizumab, vedolizumab, risankizumab, upadacitinib and ozanimod as induction options for moderate-to-severe CD; combination of infliximab with thiopurines is suggested over monotherapy for biologic-naïve patients, on the basis of SONIC and PROFILE ECCO 2024. The 2025 AGA Living Clinical Practice Guideline goes further, formally suggesting initial advanced therapy over step therapy involving corticosteroids in adults with moderate-to-severely active CD, and recommending the higher-efficacy agents (infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, vedolizumab) over the lower-efficacy ones (certolizumab pegol, upadacitinib) in the biologic-naïve setting AGA 2025. The British Society of Gastroenterology aligned in 2024. The PROFILE investigators argued in their conclusion that "top-down treatment should be considered standard of care for patients with newly diagnosed active Crohn's disease."
Protocol
Infliximab is dosed at 5 mg/kg by intravenous infusion at weeks 0, 2, and 6 for induction, then 5 mg/kg every 8 weeks for maintenance; dose can be escalated to 10 mg/kg or shortened to every-4-weekly intervals if therapeutic drug monitoring shows subtherapeutic troughs (typically <5 µg/mL) or loss of response. Subcutaneous infliximab (CT-P13 SC) is now approved for maintenance after IV induction, dosed at 120 mg every 2 weeks. Adalimumab induction is 160 mg sc at week 0, 80 mg at week 2, then 40 mg every 2 weeks (or 80 mg / 40 mg in lower-intensity induction). Combination with weight-based azathioprine (≈2–2.5 mg/kg/day) or methotrexate reduces anti-drug-antibody formation, especially against infliximab Colombel et al. 2010. Pre-treatment screening: chest X-ray plus interferon-γ release assay for latent tuberculosis, hepatitis B serology, hepatitis C, HIV, and consideration of varicella status and inactivated vaccinations before initiation.
Contraindications
Absolute: active untreated tuberculosis or other serious active infection; sepsis; severe heart failure (NYHA Class III/IV) for anti-TNF specifically. Strong relative: untreated latent TB (treat first), demyelinating disease (multiple sclerosis, optic neuritis) for anti-TNF, recent lymphoma (within 5 years) for anti-TNF + thiopurine combination. Pregnancy is not a contraindication — anti-TNF is generally continued through pregnancy, with infliximab and adalimumab now categorized as acceptable in most pregnancy guidelines because uncontrolled IBD carries greater foetal risk than the drug. Live vaccines should be avoided once therapy starts.
Failure modes
Primary non-response (failure to respond at all by induction-end, week 12–14) occurs in 10–40% across anti-TNF trials, varying by definition. Secondary loss of response occurs in 13–26% per year, driven mostly by anti-drug antibody formation accelerating clearance, with subtherapeutic troughs Kennedy et al. 2019. The PANTS cohort identified HLA-DQA1*05 carriage as a major immunogenicity risk factor for infliximab specifically. Mitigation: concomitant immunomodulator (reduces immunogenicity), therapeutic drug monitoring (proactive or reactive), dose escalation, switch within class (anti-TNF to anti-TNF) or out of class (anti-TNF to vedolizumab, ustekinumab, risankizumab, upadacitinib). Loss of response to a first anti-TNF predicts somewhat reduced response to a second.
Stakes
Two stake currencies: drug-side and disease-side. Drug-side: the historical step-up sequence routes virtually every moderate-to-severe IBD patient through repeated systemic corticosteroid courses. In the Olmsted County natural-history cohort, 28% of CD patients became steroid-dependent and 16% steroid-resistant within one year of starting steroids; 38% required CD-related surgery within that year Faubion et al. 2001. Cumulative steroid exposure produces weight gain (~40% of users in a 9,229-patient IBD survey), mood disturbance, insomnia, acne, moon facies, hypertension, hyperglycaemia, osteoporosis, cataracts and adrenal suppression. Corticosteroid exposure is independently associated with progression to stricturing disease (aHR ≈2.1) on multivariable analysis, while biologic exposure is not. Disease-side: untreated or under-treated moderate-to-severe Crohn's accumulates strictures, fistulas, abscesses, bowel resections and short-bowel syndrome over decades; quality-of-life decrements track tightly with active inflammation (the IBD-BOOST UK survey of >8,000 patients found pain and fatigue produced the largest QoL decrements; depression prevalence in CD is ~39% vs 11% general population; anxiety 24% vs 16%).
Payoff
The PROFILE arm achieved 79% sustained steroid-free, surgery-free remission at 48 weeks Noor et al. 2024. The felt translation: bowel-movement frequency falls from 6–10/day to 1–3/day within 2–6 weeks of the first infusion; nocturnal diarrhea and urgency typically resolve first; abdominal pain follows; fatigue lags but tracks resolution of inflammation over 2–4 months; weight returns. Mucosal healing on follow-up endoscopy at 6–12 months predicts longer relapse-free intervals and lower colectomy / resection rates. Depression and anxiety scores partially normalise with disease control. Five-year follow-up suggests durable benefit and no excess in serious infections or malignancy versus step-up Noor et al. 2024.
Practicalities (cost, access)
Originator infliximab and adalimumab list pricing was historically >$25,000–50,000 per patient-year in the United States; biosimilar entry (infliximab-dyyb 2016, infliximab-abda 2017, adalimumab biosimilars 2023) has compressed prices materially — by ~50–60% per infusion for infliximab originator from December 2017 to December 2021 — but coinsurance structures often leave US patient out-of-pocket cost >$3,000–5,000/year. In NHS / EU jurisdictions with biosimilar mandates, drug cost is no longer the binding constraint; the PROFILE cost-effectiveness analysis estimated top-down infliximab saved £1,681 per patient over five years at NHS prices (£10,059 with adalimumab), dominating step-up in 98.7% of model simulations at a £30,000/QALY threshold Lee et al. 2025. Infusion route burden: infliximab IV requires 2-hour infusions every 8 weeks at an infusion centre, plus ~1-hour observation; subcutaneous infliximab and adalimumab can be self-injected at home. Therapeutic drug monitoring requires periodic trough-level draws.
Misconceptions
Three persistent ones in clinical practice. (1) "Step-up is the safer default — biologics carry too much long-term risk to start early." Meta-analyses and the PROFILE 5-year follow-up show top-down does not produce excess serious infections or malignancy compared with step-up; the latter exposes the patient to more cumulative steroids and more disease-driven harms Singh et al. 2020. The risk comparison is not "biologic vs nothing" — it is "biologic vs cumulative steroids + ongoing inflammation." (2) "Biomarkers can tell us who needs top-down." PROFILE specifically tested the leading T-cell transcriptional biomarker and found no interaction with treatment effect Noor et al. 2024; every subgroup benefits. (3) "Mild disease can step up safely." This is true and explicitly outside the top-down indication; top-down is the strategy for moderate-to-severe disease, defined endoscopically and biochemically. Mild disease (CDEIS <6, normal CRP/calprotectin) is properly managed with budesonide or mesalamine and watchful escalation.
Alternatives
Within the top-down position itself, alternatives to anti-TNF + immunomodulator have proliferated. Ustekinumab (anti-IL-12/23) and the more potent IL-23-specific agents risankizumab, mirikizumab and guselkumab match anti-TNF on efficacy in moderate-to-severe CD with cleaner safety profiles (no immunogenicity-driven loss of response problem and lower infection risk). Vedolizumab (gut-selective α4β7-integrin antagonist) is the alternative when systemic immunosuppression is undesirable — older patients, prior malignancy, demyelinating disease — and is the head-to-head winner against infliximab as first-line UC therapy in retrospective comparative data. Oral JAK inhibitors (upadacitinib, tofacitinib) offer rapid onset and oral dosing, traded against a black-box warning for cardiovascular events and malignancy in older / cardiovascular-risk patients. Outside of advanced therapy entirely, treat-to-target with biomarker monitoring (CALM-style) is the partial-credit option — letting calprotectin rather than symptoms gate escalation — and accelerated step-up (the comparator in PROFILE) is what most patients still receive in practice.
History
Infliximab received FDA approval for Crohn's disease in 1998. Step-up management was the explicit standard through the late 1990s and 2000s — historically rooted in the high cost of early biologics and conservative attitudes about systemic immunosuppression. The pivotal D'Haens 2008 trial coined the "top-down" terminology by analogy to early-aggressive rheumatoid-arthritis treatment D'Haens et al. 2008. SONIC reinforced the combination-therapy advantage Colombel et al. 2010. REACT extended the case at community-practice scale Khanna et al. 2015. CALM established treat-to-target with biomarkers Colombel et al. 2017. PROFILE in 2024 was the definitive demonstration that prompted both ECCO and AGA to lean their guidelines toward early advanced therapy in 2024–25 Noor et al. 2024, ECCO 2024, AGA 2025.
The credibility range
Optimist case
The strongest pro-position is that top-down is the rare paradigm shift backed by replication across two decades, four major randomised trials (D'Haens 2008, SONIC 2010, REACT 2015, PROFILE 2024) and consistent mechanism, with the most recent and largest trial showing a 64-percentage-point absolute benefit on the most clinically meaningful endpoint (steroid-free, surgery-free remission), with fewer adverse events, fewer serious adverse events, and fewer surgeries — and now five-year safety reassurance and dominant cost-effectiveness. The "biologics are dangerous" objection that delayed adoption is empirically refuted by the safety data. The "they're too expensive" objection is increasingly refuted by biosimilar pricing and by formal cost-effectiveness analysis. Major guideline bodies have moved; the historical reluctance was a conservatism error, costing patients years of unnecessary steroid-mediated harm and bowel damage. Top-down should be the default in moderate-to-severe disease; the burden of justification has flipped to the step-up defender.
Skeptic case
Several persistent concerns. (1) The 5-year follow-up at PROFILE shows no safety signal at five years, but anti-TNF in IBD has not been followed at population scale for the 30–50-year horizon of a 25-year-old at diagnosis; rare lymphomas (hepatosplenic T-cell lymphoma with combination thiopurine + anti-TNF), late demyelinating events, and other rare delayed harms cannot be ruled out by RCT timelines. (2) PROFILE was UK-based, single-payer, NHS biosimilar pricing — its cost-effectiveness does not translate directly to US fragmented insurance. (3) The trials enrolled moderate-to-severe disease as defined by composite indices, CRP, calprotectin and endoscopy; the criteria don't perfectly identify the patient who would never have progressed under step-up — meaning a fraction of top-down patients receive lifelong biologic for disease that would have been mild. (4) Biomarker stratification was the field's hope to solve that overtreatment problem and failed in PROFILE; no current tool reliably identifies the indolent subset. (5) Anti-TNF immunogenicity remains an issue — primary non-response 10–40%, secondary loss 13–26%/year — so "top-down" does not mean "set and forget," and the patient committing to it implicitly commits to therapeutic drug monitoring, possible switching, and sometimes failure. (6) Step-up enthusiasts argue that accelerated step-up (with calprotectin-gated escalation, as in PROFILE's comparator) would catch most cases without exposing low-risk patients to upfront biologics; PROFILE's data refute this but the philosophical objection persists.
Author's call
For moderate-to-severe IBD at diagnosis, the evidence converges on top-down as the default. Four positive trials over twenty years, the largest of them PROFILE at 386 patients with a 64-percentage-point effect size, plus five-year safety data showing no excess infection or malignancy versus step-up, plus formal cost dominance, plus aligned ECCO 2024 and AGA 2025 guidelines, places this in the rare "evidence base strong enough to inform a default" category — `evidence: 5`. Residual controversy is real but moderate (`controversy: 2`): the long-term-safety horizon is genuinely incomplete, biomarker stratification has not delivered, and a meaningful minority of patients will receive lifelong therapy for disease they might have managed lighter. These caveats do not weaken the case enough to defend step-up as the default in moderate-to-severe disease. The article will frame top-down as the strategy to advocate for at diagnosis when disease meets the moderate-to-severe threshold, will keep mild disease explicitly out of scope, and will be honest about the residual unknowns.
Stakeholder and incentive map
- Pharmaceutical industry — originator biologic manufacturers (Janssen for infliximab/Remicade and ustekinumab/Stelara; AbbVie for adalimumab/Humira and risankizumab/Skyrizi; Takeda for vedolizumab/Entyvio; Pfizer for tofacitinib; Eli Lilly for mirikizumab) have funded the trials and have direct commercial interest in early-and-broader adoption. SONIC, ACCENT, several PROFILE-related analyses had industry funding; trial conduct quality is generally high but the source matters for transparency.
- Biosimilar manufacturers — opposite incentive on price, aligned incentive on broader prescription. Their market entry has been the principal force collapsing biologic cost.
- Gastroenterology professional societies — ECCO, AGA, BSG, ACG have moved toward early advanced therapy across 2024–25; this reflects evidence but also the field's identity as "the specialty that uses biologics" relative to alternatives (surgeons, dieticians).
- Payers / insurers — historically incentivised step-up via prior-authorisation requirements and step-edit policies; under biosimilar pricing and PROFILE cost-effectiveness, the incentive is starting to flip. US fragmented insurance still creates patient-facing financial toxicity.
- Patient advocacy — Crohn's & Colitis Foundation and equivalent UK / EU bodies have advocated for earlier biologic access; aligned with top-down.
- Skeptic / counter-incentive — primary-care physicians and older gastroenterologists trained in the step-up era; alternative-medicine and diet-first communities (some of which medicalise IBD outside the inflammatory-disease frame); and a smaller heterodox subset arguing biologics are over-prescribed.
Population variability
Demographics. Peak IBD diagnosis falls in the 15–35 age band; a smaller second peak in 50s–60s. Crohn's slightly female-predominant in adults, UC slightly male-predominant; effect not large enough to gender-scope the entry.
Disease severity. Top-down applies to moderate-to-severe IBD at diagnosis — Crohn's Disease Activity Index ≥220 / Harvey-Bradshaw Index ≥7 / total Mayo score ≥6 in UC, plus objective inflammation (elevated CRP, calprotectin, endoscopic disease). Mild disease is outside scope and step-up appropriate.
Phenotype. Stricturing or penetrating Crohn's behaviour at diagnosis (B2, B3 in the Montreal classification), perianal disease, ileal location, early extensive UC, and young age at diagnosis are all independent predictors of more aggressive course and stronger top-down candidates.
Comorbidities. Older patients (≥60), cardiovascular comorbidity, prior malignancy, demyelinating disease all shift the agent choice within the top-down position — typically toward vedolizumab or ustekinumab — rather than against the strategy itself.
Pregnancy. Anti-TNF and other biologics are continued through pregnancy in current ECCO and AGA guidance; uncontrolled IBD is a greater fetal risk than the medication.
Pediatric IBD. The strategy applies; pediatric trials (Lee 2015 single-centre, ongoing multicentre work) show similar benefit. Outside this entry's adult scope but worth flagging.
Knowledge gaps
Several remain. (1) The 30–50-year horizon of safety is not directly studied; only the 5-year PROFILE follow-up and registry / pharmacovigilance data extrapolate forward. (2) Biomarker-driven personalization failed in PROFILE; a tool to identify the indolent moderate-to-severe disease that would never have progressed under step-up has not emerged. (3) Optimal de-escalation strategy is not established — the SPARE trial (Louis et al., Lancet Gastro Hepatol 2023) showed thiopurine withdrawal is safer than infliximab withdrawal at year 2 of combination therapy, but durable monotherapy regimens and full discontinuation criteria remain under study. (4) Head-to-head comparisons between top-down agent classes (anti-TNF vs anti-IL-23 vs anti-integrin) in the newly-diagnosed top-down position are largely absent; observational and indirect-comparison data dominate. (5) UC top-down has weaker direct RCT evidence than CD — most extrapolation is from observational cohorts and the UC literature on individual biologics. (6) The optimal handling of the patient who fails first-line top-down (primary non-response or early secondary loss) is heterogeneous in practice.
Scope decisions. The brief named several consequences (mucosal healing, surgery rates, steroid exposure, long-term complications, side-effect profile). The article covers all five — mucosal healing in protocol and payoff, surgery and complications in stakes and evidence, steroid exposure throughout but principally in stakes, side-effect profile in contraindications and failure-modes. Top-down is treated as a strategy rather than a single drug; the article centres anti-TNF as the most-studied option but covers anti-IL-23, vedolizumab, and JAK inhibitors as substitutable in the same position.
Mild disease deliberately out of scope. The whole evidence base — D'Haens 2008, SONIC 2010, REACT 2015, CALM 2017, PROFILE 2024 — enrolled moderate-to-severe disease. Top-down is not recommended for mild disease and the entry says so explicitly in misconceptions. A separate entry on "managing mild IBD" would be useful eventually.
Ulcerative colitis evidence is thinner. The largest top-down RCTs were in Crohn's. UC top-down evidence comes from observational cohorts and individual-drug RCTs (ACT 1/2 for infliximab; GEMINI for vedolizumab). The article notes vedolizumab is often preferred first-line in UC. A dedicated UC top-down entry, once the ongoing pediatric and adult UC RCTs report, may be warranted.
Rating difficulties. Cadence was a hard call. The strategic decision is once at diagnosis; the medication continues indefinitely. Picked "once" because the entry's purpose is to help the reader make the one-time decision; the drug schedule itself is described under protocol. Contraindications vocabulary doesn't include "active-infection", "tuberculosis", "demyelinating-disease", or "lymphoma-history" which are the real anti-TNF contraindications; settled on cardiac-condition as the closest fit (severe heart failure being a documented anti-TNF contraindication) and covered the rest as prose in the contraindications addressing section.
Adjacent entries flagged for future work. Faecal calprotectin testing, therapeutic drug monitoring for biologics, exclusive enteral nutrition in Crohn's, smoking and IBD, iron-deficiency anaemia in IBD, and the IBD–depression / IBD–anxiety axis are all named in out-of-scope. None of these exists in the catalogue yet; once they do, this entry should link back to them.
Cost framing. The cost picture is jurisdiction-dependent in a way the catalogue doesn't normally encode. The article handles this by giving both the US picture (high but compressing, patient-assistance programmes available) and the UK / EU picture (biosimilars dominate, cost-effective or cost-saving). Reader experience differs more by country than by individual case here.
5-year PROFILE follow-up data. Cited from ECCO 2026 conference presentation (Noor et al.), which is not yet a peer-reviewed publication. Flagged in the research dossier; the article treats the safety reassurance as preliminary rather than definitive. If the formal publication appears, swap the framing accordingly.
Top-Down Biologic Therapy for IBD
Going from eight bloody bowel movements a day to one normal one within weeks. Few interventions in medicine flip a daily reality this fast.
Four major randomised trials over twenty years all point the same way; the largest (2024) showed 79% in lasting remission vs 15% on the old approach.
Active inflammatory bowel disease is profoundly tiring. Most people who reach remission describe getting the lost gear of their day back.
Active disease drives anxiety and depression at roughly double the general-population rate. Remission lifts much of it; the bowel and the head improve together.
An infusion every two months at a clinic, or a self-injection every two weeks at home. Plus periodic blood tests and colonoscopy. Real but not lifestyle-dominating.
Lowers the colorectal-cancer risk that comes with decades of gut inflammation, and avoids the bone, heart and metabolic damage from cumulative steroid courses.
The brain fog that comes with chronic gut inflammation lifts when the inflammation does. Avoiding repeated steroid courses helps further.
Night diarrhea, urgency and pain stop waking you. Steroid-induced insomnia never gets started in the first place.
No more oral ulcers, perianal flares, or steroid-driven acne and moon face. Healing inflammation early restores how the disease shows on your skin.
Surgery scars, ostomy bags, and decades of steroid-thinned skin and brittle bones never accumulate when the disease is shut down at diagnosis.
Even with biosimilars and good insurance, expect thousands of dollars a year out of pocket in the US; cheaper in single-payer systems where biosimilars dominate.